Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Oncotelic Therapeutics, Inc. | d506519d10k.htm |
| EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | d506519dex312.htm |
| EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | d506519dex311.htm |
| EX-23.1 - EX-23.1 - Oncotelic Therapeutics, Inc. | d506519dex231.htm |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2017 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: April 17, 2018 |
/s/ WILLIAM D. SCHWIETERMAN |
|||||
| William D. Schwieterman, President and Chief Executive Officer | ||||||
| Date: April 17, 2018 |
/s/ MATTHEW M. LOAR |
|||||
| Matthew M. Loar, Chief Financial Officer | ||||||